Clinical-Stage Biotech (Nasdaq: INDP) Has 5 Potential Catalysts To Consider Immediately (Low Float)

That's how you kick the week off!

*Sponsored StockWireNews Clinical-Stage Biotech (Nasdaq: INDP) Has 5 Potential Catalysts To Consider Immediately (Low Float) March 19th Greetings Readers, That's how you kick the week off! Tracking a Nasdaq low float profile heading into the weekend, it's breakout potential was too impressive to not share. After it closed in after hours Friday at $1.71, it catapulted like a frog in a dynamite pond to a high of $3.50 come Monday. Some quick math will tell you that's a surge of approx. 104%! Not bad, but there's no time to gloat as another Nasdaq profile just grabbed my attention. Here's what to focus on immediately: #1. At least 2 different analysts are suggesting triple-digit potential upside from current chart levels. #2. A low float could create a daily environment for heightened volatility potential. #3. Positive news early in 2025 on the heels of a head-turning 2024 corporate update paints this company as one to watch in the near term. Ready to know what I'm tracking next? Take a look at: *Indaptus Therapeutics, Inc. (Nasdaq: INDP)* Indaptus Therapeutics Inc is a pre-clinical biotechnology company focused on developing innovative anti-cancer and anti-viral immunotherapies. And based on several potential catalysts, INDP has jumped to the top of my watchlist this week. Check them out: No. 1 - Will A Low Float Provide The Possibility Of A Volatile Environment? No. 2 - A Recent Company Update Paints A Promising Picture Of The Future After 2024 Accomplishments. No. 3 - A Pair Of Analyst Targets Suggest Significant Upside Potential From Current INDP Chart Levels. No. 4 - Securing New Patent Approvals For The Decoy Platform Highlights Company's Detailed Approach. No. 5 - INDP Receives Critical Approval To Expand Decoy20 Clinical Trial. But more on those in a second... Indaptus Therapeutics Company Overview The Indaptus Goal is Simple: to Cure Disease With the ability to harness both the body's innate and adaptive immune responses, Indaptus believes they are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. Building on the observation that tumor regression can occur in the setting of bacterial infection, they have developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. Leveraging their novel insights into the levels and ratios of activating signals needed to safely elicit a broad immune response, Indaptus is creating and advancing a pipeline of proprietary, attenuated and killed non-pathogenic gram-negative bacterial candidates designed to be widely accessible, with broad anti-tumor and anti-viral activity.

Their candidates, including their lead candidate Decoy20, have demonstrated, in pre-clinical studies, the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models. Indaptus believes that their Decoy candidates are unique in their ability to synergize with each of a wide variety of existing therapies, including checkpoint therapy and targeted antibodies, to produce durable anti-tumor responses against established tumors, with induction of both innate and adaptive immunological memory. Indaptus initiated their Phase 1 clinical trial of Decoy20 in December 2022 and dosed their first patient in March 2023.

Key Milestones ✓ First dosing of Decoy20 in Q1 2023 ✓ Initial single dose safety data 2H 2023 · Multi-cohort single dose safety data 1H 2024 · Multi-dose safety data 2H 2024 · Combo Data Proof of Concepts in late 2025 / early 2026

Indaptus' Immunotherapy Pipeline

Find Sources And More: INDP Website. INDP Presentation. ----- And as I mentioned above, (Nasdaq: INDP) has several potential catalysts to consider right now. Take a look: No. 1 INDP Potential Catalyst - Will A Low Float Provide The Possibility Of A Volatile Environment? According to info from Yahoo Finance website, INDP has a low float. In fact, the website reports this profile to have approx. 7.89Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. ----- No. 2 INDP Potential Catalyst - A Recent Company Update Paints A Promising Picture Of The Future After 2024 Accomplishments. Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20 Pharmacodynamic immune activation biomarker and pharmacokinetics profiles in initial data sets appear to meet or exceed initial expectations Early signs of potential benefit emerge with some patients demonstrating Stable Disease NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company") today announces financial results for the fourth quarter and fiscal year ended December 31, 2024 and provides a corporate update. Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, "We continue to make significant progress in our Phase 1 trial of Decoy20, and enrolling more than 20 patients in the weekly dosing cohort marks an important milestone. We are particularly encouraged by the emerging clinical data, with some patients in this cohort demonstrating stable disease - an early sign that Decoy20's immune-modulating approach may be having a meaningful impact. With a favorable safety profile observed so far, we are focused on efficiently advancing our trial and exploring Decoy20's potential, both as a monotherapy and in combination therapy in difficult-to-treat cancers. We look forward to generating additional data in the months ahead as we prepare to initiate our planned combination trial with BeiGene's PD-1 inhibitor, tislelizumab." Key recent highlights: Successfully advanced Phase 1 study of Decoy20 in advanced solid tumors, with weekly dosing now underway following a positive Safety Review Committee assessment. Achieved key milestone with more than 20 patients enrolled in the weekly dosing cohort among the two Decoy20 dose levels, further supporting the clinical evaluation of Decoy20's safety and activity. Additionally, early signs of potential benefit emerge with some patients with Stable Disease. Entered clinical supply agreement with BeiGene to advance Decoy20 for its evaluation in combination with BeiGene's PD-1 inhibitor, tislelizumab, for use in multiple cancer types, with trial initiation expected in 2025. Secured new patents in China, Japan and Israel, covering Decoy bacteria compositions for the prevention or treatment of Hepatitis B vi-rus (HBV) and human immunodeficiency vi-rus (HIV), further expanding and reinforcing the company's intellectual property position. Received Clinical Trial authorization from Health Canada, clearing the Company for expansion of clinical trial sites and broader patient recruitment. Presented promising PK, pharmacodynamic, and safety results for Decoy20 at the American Society for Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC) annual meetings. Published data in Frontiers in Immunology demonstrating the pre-clinical pharmacodynamic, mechanism of action, and safety results for the Decoy platform. Successfully completed multiple financings throughout the past year, including registered direct offerings and an equity line, bolstering financial flexibility. ... Read the full article here. ----- No. 3 INDP Potential Catalyst - A Pair Of Analyst Targets Suggest Significant Upside Potential From Current INDP Chart Levels. Over at Zacks, the website is reporting these key analyst targets:

With two separate targets suggesting over 500% potential upside from INDP's opening valuation on Monday, March 17th, it may be the perfect time to consider this biotech company for your watchlist. ----- No. 4 INDP Potential Catalyst - Securing New Patent Approvals For The Decoy Platform Highlights Company's Detailed Approach. Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announced today that it has secured new patent approvals in China, Japan and Israel for its Decoy platform. These patents cover the use of Decoy bacteria compositions for preventing or treating Hepatitis B vi-rus (HBV) and human immunodeficiency vi-rus (HIV) – two diseases that continue to pose major global health challenges. The patents also extend to combination therapies with a variety of both approved and investigational treatments. Dr. Michael Newman, Founder and Chief Scientific Officer of Indaptus, commented, "The allowance of these patents in key international markets highlights the potential of our Decoy platform in the fight against chronic infectious diseases. With millions of people affected by HBV and HIV worldwide, expanding our intellectual property reinforces the novelty and therapeutic promise of our approach." ... Read the full article here. ----- No. 5 INDP Potential Catalyst - INDP Receives Critical Approval To Expand Decoy20 Clinical Trial Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the Company has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20. This approval will allow the Company to expand its ongoing U.S. clinical trial, INDP-D101, to Canadian sites, broadening patient recruitment and enhancing its clinical research program. The trial will enroll patients in Canada under the current protocol, which involves weekly dosing of Decoy20. Indaptus also plans to submit an amendment to Health Canada to incorporate its upcoming combination trial, which pairs Decoy20 with Beigene's PD-1 checkpoint inhibitor, tislelizumab. Jeffrey Meckler, CEO of Indaptus, commented, "We are pleased to bring Canadian investigators and patients into our clinical efforts, creating a more diverse and robust data set. Health Canada's approval followed a comprehensive review of our safety data and trial design. Expanding to Canada represents a significant step in our mission to evaluate Decoy20, a broad immune system activator, in patients with solid tumors." ... Read the full article here. ----- (Nasdaq: INDP) Recap - 5 Potential Catalysts Of Focus No. 1 - Will A Low Float Provide The Possibility Of A Volatile Environment? No. 2 - A Recent Company Update Paints A Promising Picture Of The Future After 2024 Accomplishments. No. 3 - A Pair Of Analyst Targets Suggest Significant Upside Potential From Current INDP Chart Levels. No. 4 - Securing New Patent Approvals For The Decoy Platform Highlights Company's Detailed Approach. No. 5 - INDP Receives Critical Approval To Expand Decoy20 Clinical Trial. ----- Coverage is officially initiated on Indaptus Therapeutics, Inc. (Nasdaq: INDP). When updates pop up, I'll get them out quickly. Talk again shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews.com ("StockWireNews" or "SWN" ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/18/2025 and ending on 03/19/2025 to publicly disseminate information about (INDP:US) via digital communications. Under this agreement, SWN Media LLC has been paid fifteen thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (INDP:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/indp/#details Unsubscribe Stock Wire News 160 West Camino Real Unit 886 Boca Raton, Florida 33432 United States